LCE enters the final days of April with a concrete operational catalyst — and a short interest picture that has dramatically quieted after weeks of volatile positioning.
The story this week belongs to the demonstration plant. On April 23, Century Lithium announced it is relocating its demonstration plant to Tonopah, Nevada, and provided an updated reagent cost structure for the Angel Island lithium project. The move is a tangible step forward for a company that has been largely range-bound at CAD 0.365 — flat over the past month after a 1.4% gain on the week. Noble Financial followed with a Buy rating on April 27, the only notable analyst action on record. That lone endorsement, with no sell-side coverage from larger institutions, leaves the stock with a thin analyst support structure heading into its May 8 earnings event.
Short interest here is a minor side note, not the headline. At roughly 0.04% of free float — just 63,600 shares short as of April 28 — there is almost no bearish positioning by conventional measures. What is interesting is the violent path that number has taken. In mid-March, short interest ran close to 0.28% of float. By April 13 it had collapsed to near zero, briefly rebounded to 0.13% in early April during the broader market stress period, and has since wound back down sharply again. The 30-day change is an 87% decline. This is not a squeeze story — it is a stock where even a very small number of shorts have been actively repositioning around price volatility.
The borrow market reflects the lack of pressure. Cost to borrow has eased to 2.83% from a month-ago level above 5%, and availability looks comfortable — borrow availability has been loosening alongside the decline in short shares outstanding. The 52-week peak in borrow utilization reached 93%, but the current reading of 36% is well off that extreme. In practical terms, the lending market presents no friction for would-be shorts, and no squeeze dynamic is in play.
The ORTEX short score of 41.6 is mid-range, having bounced from lows near 27 in mid-April when short interest briefly collapsed. That recovery in the score tracks the modest rebuilding of short shares through late April. Factor scores offer little additional signal: the utilization rank of 18 and short score rank of 22 both sit in the lower third of the universe, consistent with a stock that is lightly shorted by any metric. Valuation data is stale (last updated May 2024), so multiples are not actionable here.
The most recent insider activity is dated — a director sale in October 2025 and a cluster of small director purchases through August 2025 — and at those values (sub-$22,000 each) they do not materially change the ownership picture. Canton Hathaway LLC added 195,000 shares as of March 31, the only fresh institutional move in the holder list, but at 0.11% of shares it is a small increment.
Among correlated peers, the week was mostly negative. HOC fell 11% on the week and ERD dropped 11.6%, while LAC held relatively steady at -0.7%. LCE's modest 1.4% gain looks like modest outperformance in a weak peer group. Recent earnings history shows a mixed but positive tilt — the last two events produced 1-day moves of +1.3% and +2.9%, though a November 2025 print fell 8.5% on the day. The May 8 release is therefore the next genuine focus point: whether the Tonopah relocation and updated reagent costs translate into a constructive operational narrative will determine whether the recent calm in positioning holds.
See the live data behind this article on ORTEX.
Open LCE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
